JP2015537190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015537190A5 JP2015537190A5 JP2015533163A JP2015533163A JP2015537190A5 JP 2015537190 A5 JP2015537190 A5 JP 2015537190A5 JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015537190 A5 JP2015537190 A5 JP 2015537190A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antibody
- tnf
- variant
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 31
- 102220499015 Ankyrin repeat domain-containing protein 33B_A11S_mutation Human genes 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 208000025705 Axial Spondyloarthritis Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 201000002661 Spondylitis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 32
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 8
- 102220516769 Protein-arginine deiminase type-1_Y11F_mutation Human genes 0.000 description 5
- 102220511193 Putative nuclease HARBI1_G17S_mutation Human genes 0.000 description 5
- 102220538710 Superoxide dismutase [Cu-Zn]_V15M_mutation Human genes 0.000 description 5
- 102220533950 T cell receptor beta variable 11-3_V15Q_mutation Human genes 0.000 description 5
- 102220502005 U3 small nucleolar RNA-interacting protein 2_E16R_mutation Human genes 0.000 description 5
- 102220506777 Vitelline membrane outer layer protein 1 homolog_Y11A_mutation Human genes 0.000 description 5
- 102220365920 c.50G>C Human genes 0.000 description 5
- 102200109614 rs121909521 Human genes 0.000 description 5
- 102200131546 rs121912453 Human genes 0.000 description 5
- 102200096287 rs154774636 Human genes 0.000 description 5
- 102220298347 rs201415443 Human genes 0.000 description 5
- 102200060442 rs2227580 Human genes 0.000 description 5
- 102220086657 rs864622656 Human genes 0.000 description 5
- 102220362974 c.37G>A Human genes 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 102220254429 rs1553156840 Human genes 0.000 description 4
- 102220049501 rs587784381 Human genes 0.000 description 4
- 101150083809 D10L gene Proteins 0.000 description 3
- 101100327163 Oryza sativa subsp. japonica CCD8A gene Proteins 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 102220275318 rs1270851643 Human genes 0.000 description 3
- 102220208982 rs368501116 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000012004 kinetic exclusion assay Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703170P | 2012-09-19 | 2012-09-19 | |
| US61/703,170 | 2012-09-19 | ||
| PCT/US2013/060480 WO2014047222A2 (en) | 2012-09-19 | 2013-09-18 | Methods for identifying antibodies with reduced immunogenicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015537190A JP2015537190A (ja) | 2015-12-24 |
| JP2015537190A5 true JP2015537190A5 (OSRAM) | 2016-11-04 |
Family
ID=49304336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533163A Pending JP2015537190A (ja) | 2012-09-19 | 2013-09-18 | 低減された免疫原性を有する抗体を同定するための方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9279016B2 (OSRAM) |
| EP (2) | EP2897978B1 (OSRAM) |
| JP (1) | JP2015537190A (OSRAM) |
| KR (1) | KR20150056788A (OSRAM) |
| CN (1) | CN104704000A (OSRAM) |
| AU (1) | AU2013318147B2 (OSRAM) |
| BR (1) | BR112015005857A2 (OSRAM) |
| CA (1) | CA2885422A1 (OSRAM) |
| CY (1) | CY1118893T1 (OSRAM) |
| DK (1) | DK2897978T3 (OSRAM) |
| ES (1) | ES2621285T3 (OSRAM) |
| HR (1) | HRP20170937T1 (OSRAM) |
| HU (1) | HUE032569T2 (OSRAM) |
| IL (1) | IL237833A0 (OSRAM) |
| IN (1) | IN2015DN01967A (OSRAM) |
| LT (1) | LT2897978T (OSRAM) |
| MX (1) | MX2015003541A (OSRAM) |
| NZ (1) | NZ705606A (OSRAM) |
| PL (1) | PL2897978T3 (OSRAM) |
| PT (1) | PT2897978T (OSRAM) |
| RS (1) | RS56093B1 (OSRAM) |
| RU (1) | RU2648141C2 (OSRAM) |
| SG (1) | SG11201502094TA (OSRAM) |
| SI (1) | SI2897978T1 (OSRAM) |
| SM (1) | SMT201700255T1 (OSRAM) |
| TW (1) | TWI519646B (OSRAM) |
| WO (1) | WO2014047222A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110382696B (zh) * | 2017-03-07 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 发现替代性抗原特异性抗体变体的方法 |
| TW202039554A (zh) * | 2018-12-19 | 2020-11-01 | 瑞士商諾華公司 | 抗ＴＮＦ－α抗體 |
| EP3997124A4 (en) * | 2019-07-09 | 2024-01-03 | National Institute for Biotechnology in the Negev Ltd. | ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| EP4037699A1 (en) | 2019-09-30 | 2022-08-10 | SciRhom GmbH | Protein binders to irhom2 epitopes |
| FR3104582A1 (fr) * | 2019-12-17 | 2021-06-18 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Variants de l’adalimumab au potentiel immunogène réduit |
| CN113125714B (zh) * | 2019-12-31 | 2023-06-16 | 科美博阳诊断技术(上海)有限公司 | 一种人类免疫缺陷病毒抗体检测试剂盒及其应用 |
| WO2021147642A1 (en) * | 2020-01-20 | 2021-07-29 | Bio-Thera Solutions, Ltd. | Methods, models and systems related to antibody immunogenicity |
| KR102568430B1 (ko) * | 2020-11-16 | 2023-08-24 | 바디텍메드(주) | 항 약물 항체의 신속 검출 방법 |
| CA3208070A1 (en) | 2021-03-01 | 2022-09-09 | Matthias Schneider | Humanized antibodies against irhom2 |
| CA3213771A1 (en) | 2021-03-29 | 2022-10-06 | Scirhom Gmbh | Methods of treatment using protein binders to irhom2 epitopes |
| WO2022214664A1 (en) | 2021-04-09 | 2022-10-13 | Philogen S.P.A. | Improved interferon-gamma mutant |
| WO2024023246A1 (en) | 2022-07-28 | 2024-02-01 | Philogen S.P.A. | Antibody binding to pd1 |
| KR20250049549A (ko) | 2022-08-08 | 2025-04-11 | 에이티비 테라퓨틱스 | CD79b에 대한 인간화된 항체 |
| WO2025180665A1 (en) | 2024-02-28 | 2025-09-04 | Evotec International Gmbh | Antibodies binding to cd2, and multifunctional molecules comprising such antibodies |
| WO2025242726A1 (en) | 2024-05-21 | 2025-11-27 | Onconick Ltd. | Antibody binding to FGFR1 and conjugates comprising the same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| EP0189330B1 (en) | 1985-01-25 | 1992-12-02 | The Kitasato Institute | Antitumor antibiotics and their production |
| US5264357A (en) | 1985-05-24 | 1993-11-23 | Genentech, Inc. | Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6787308B2 (en) | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7211390B2 (en) | 1999-09-16 | 2007-05-01 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
| EP1218543A2 (en) | 1999-09-29 | 2002-07-03 | Solexa Ltd. | Polynucleotide sequencing |
| US6686168B1 (en) | 1999-11-04 | 2004-02-03 | Zymogenetics, Inc. | Cell surface display of proteins by recombinant host cells |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| WO2002027029A2 (en) | 2000-09-27 | 2002-04-04 | Lynx Therapeutics, Inc. | Method for determining relative abundance of nucleic acid sequences |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6956114B2 (en) | 2001-10-30 | 2005-10-18 | '454 Corporation | Sulfurylase-luciferase fusion proteins and thermostable sulfurylase |
| US7057026B2 (en) | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| AU2003283995A1 (en) | 2002-09-30 | 2004-04-19 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| TWI439284B (zh) * | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| ES2340205T3 (es) | 2005-11-12 | 2010-05-31 | Eli Lilly And Company | Anticuerpos anti-egfr. |
| JP5759722B2 (ja) * | 2007-08-28 | 2015-08-05 | アッヴィ バイオテクノロジー リミテッド | アダリムマブの結合蛋白質を含む組成物及び方法 |
| WO2009059235A2 (en) | 2007-11-01 | 2009-05-07 | Facet Biotech Corporation | Immunoglobulin display vectors |
| EP2918602A1 (en) | 2009-04-16 | 2015-09-16 | AbbVie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| BR112012022917A2 (pt) * | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| RU2584597C2 (ru) * | 2010-08-13 | 2016-05-20 | Рош Гликарт Аг | Антитела против а2 тенасцина с и способы их применения |
| EA201300470A1 (ru) * | 2010-10-20 | 2014-05-30 | Оксфорд Байотерепьютикс Лтд. | Антитела |
-
2013
- 2013-09-18 IN IN1967DEN2015 patent/IN2015DN01967A/en unknown
- 2013-09-18 SG SG11201502094TA patent/SG11201502094TA/en unknown
- 2013-09-18 PL PL13773474T patent/PL2897978T3/pl unknown
- 2013-09-18 HU HUE13773474A patent/HUE032569T2/en unknown
- 2013-09-18 RS RS20170609A patent/RS56093B1/sr unknown
- 2013-09-18 WO PCT/US2013/060480 patent/WO2014047222A2/en not_active Ceased
- 2013-09-18 EP EP13773474.5A patent/EP2897978B1/en active Active
- 2013-09-18 EP EP17154662.5A patent/EP3211006A3/en not_active Withdrawn
- 2013-09-18 NZ NZ705606A patent/NZ705606A/en not_active IP Right Cessation
- 2013-09-18 TW TW102134040A patent/TWI519646B/zh not_active IP Right Cessation
- 2013-09-18 HR HRP20170937TT patent/HRP20170937T1/hr unknown
- 2013-09-18 DK DK13773474.5T patent/DK2897978T3/en active
- 2013-09-18 US US14/030,977 patent/US9279016B2/en not_active Expired - Fee Related
- 2013-09-18 LT LTEP13773474.5T patent/LT2897978T/lt unknown
- 2013-09-18 CA CA2885422A patent/CA2885422A1/en not_active Abandoned
- 2013-09-18 JP JP2015533163A patent/JP2015537190A/ja active Pending
- 2013-09-18 ES ES13773474.5T patent/ES2621285T3/es active Active
- 2013-09-18 CN CN201380048863.XA patent/CN104704000A/zh active Pending
- 2013-09-18 SM SM20170255T patent/SMT201700255T1/it unknown
- 2013-09-18 RU RU2015111671A patent/RU2648141C2/ru not_active IP Right Cessation
- 2013-09-18 SI SI201330608A patent/SI2897978T1/sl unknown
- 2013-09-18 AU AU2013318147A patent/AU2013318147B2/en not_active Ceased
- 2013-09-18 MX MX2015003541A patent/MX2015003541A/es unknown
- 2013-09-18 KR KR1020157007286A patent/KR20150056788A/ko not_active Withdrawn
- 2013-09-18 PT PT137734745T patent/PT2897978T/pt unknown
- 2013-09-18 BR BR112015005857A patent/BR112015005857A2/pt active Search and Examination
-
2015
- 2015-03-19 IL IL237833A patent/IL237833A0/en unknown
-
2017
- 2017-04-11 CY CY20171100428T patent/CY1118893T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015537190A5 (OSRAM) | ||
| RU2015111671A (ru) | Способы идентификации антител с пониженной иммуногенностью | |
| AU2016223095B2 (en) | Antibodies to tau and uses thereof | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| JP2018510868A (ja) | 二重特異性抗体を精製する方法 | |
| KR20130010123A (ko) | ＴＮＦ-α 결합 단백질 | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| JP2009509538A5 (OSRAM) | ||
| CN113912731A (zh) | 一种抗fgl1抗体及其应用 | |
| JP2018148915A (ja) | 抗ｖａｓａ抗体、ならびにその産生法および使用法 | |
| JP2022512672A (ja) | アントラサイクリンを含む結合タンパク質－毒素融合体、および免疫腫瘍学的適用におけるその使用 | |
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 | |
| TW202045132A (zh) | 生成包含有兩種或更多種抗體的組成物之技術 | |
| CN104558172A (zh) | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 | |
| JPWO2021133723A5 (OSRAM) | ||
| AU2020322765A1 (en) | Bispecific antibody | |
| CN118085082A (zh) | 抗猫TNF-α单克隆抗体及其应用 | |
| JP2020505465A5 (OSRAM) | ||
| US20130109586A1 (en) | Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid | |
| TWI773264B (zh) | 結合人ngf的抗體、其製備方法和用途 | |
| CN119930817B (zh) | Tigit全人源抗体及其制备方法与应用 | |
| CN115386003B (zh) | 抗SARS-CoV-2鼠源单克隆抗体及其应用 | |
| CN119233987B (zh) | 抗α-Synuclein抗体及其用途 | |
| AU2024214278A1 (en) | Human anti-pd-l2 antibody and its uses thereof |